The global peptide manufacturing industry is in the middle of its largest expansion ever. Driven by insatiable demand for GLP-1 drugs and a growing clinical pipeline, companies are investing billions to build new production facilities.
This article tracks the major capacity expansions, technology innovations, and workforce challenges shaping peptide manufacturing in 2026.
- Over $15 billion in peptide manufacturing investments announced since 2023
- Global SPPS capacity is expected to double by 2028
- Novo Nordisk and Eli Lilly are the largest investors in dedicated capacity
- CDMOs are expanding to capture growing outsourcing demand
- Workforce shortages threaten to delay capacity buildout timelines
The Capacity Crisis
Demand for peptide drugs has outstripped manufacturing capacity since 2023. The FDA has listed semaglutide and tirzepatide on its drug shortage list multiple times, highlighting the severity of the supply gap.
The root cause is simple: peptide manufacturing is complex, slow to build, and requires specialized expertise. You cannot convert a small molecule factory to peptide production overnight. New facilities take 2 to 4 years to plan, build, qualify, and bring online.
Supply-Demand Gap
| Year | Estimated Global Demand (kg) | Estimated Global Capacity (kg) | Gap |
|---|---|---|---|
| 2023 | 45,000 | 38,000 | -18% |
| 2024 | 62,000 | 48,000 | -23% |
| 2025 | 80,000 | 60,000 | -25% |
| 2026 (projected) | 95,000 | 72,000 | -24% |
| 2028 (projected) | 120,000 | 115,000 | -4% |
The gap is expected to narrow significantly by 2028 as new facilities come online, but near-term shortages will persist.
A single year's supply of semaglutide for the global market requires approximately 50 tons of peptide API. Manufacturing this quantity requires facilities that simply did not exist five years ago.
Major Investment Announcements
Pharmaceutical Companies
Novo Nordisk and Eli Lilly are making the largest investments in dedicated peptide manufacturing capacity.
| Company | Investment | Location | Timeline | Focus |
|---|---|---|---|---|
| Novo Nordisk | $6.2 billion | Denmark, US, France | 2024 to 2028 | GLP-1 API and drug product |
| Eli Lilly | $4.5 billion | US, Ireland | 2024 to 2027 | Tirzepatide production |
| AstraZeneca | $1.0 billion | US, UK | 2025 to 2028 | Peptide pipeline |
| Sanofi | $800 million | France, Germany | 2025 to 2027 | Peptide API |
CDMOs
Contract manufacturers are investing heavily to capture outsourcing demand from companies that cannot build their own facilities.
| CDMO | Investment | Location | Capacity Addition |
|---|---|---|---|
| Bachem | $1.2 billion | Switzerland, US | 3x current capacity |
| PolyPeptide Group | $800 million | Sweden, India, US | 2x current capacity |
| Corden Pharma | $400 million | Germany, US | 2x current capacity |
| Samsung Biologics | $500 million | South Korea | New peptide division |
| WuXi AppTec | $300 million | China | 2x current capacity |
New Market Entrants
Several companies are entering peptide manufacturing for the first time:
- Traditional small molecule CDMOs adding peptide capabilities
- Biologics manufacturers diversifying into peptides
- New standalone peptide manufacturing startups backed by VC funding
Technology Innovations
Continuous Flow Synthesis
Traditional batch SPPS is being supplemented by continuous flow methods that offer faster cycle times and better process control.
Continuous flow synthesis uses microreactors or packed-bed columns for peptide coupling reactions. The advantages include:
- Faster reactions (minutes vs hours per coupling)
- Better heat and mass transfer
- Smaller equipment footprint
- Real-time process monitoring
- Reduced solvent consumption
Several CDMOs are implementing continuous flow for specific synthesis steps, though fully continuous peptide manufacturing remains an area of active development.
Liquid Phase Peptide Synthesis (LPPS)
Liquid phase synthesis at large scale is making a comeback for certain peptide sequences. LPPS avoids the costs of solid supports and can be more economical for production-scale manufacturing of shorter peptides.
Hybrid approaches that combine LPPS for fragment synthesis with SPPS for final assembly are gaining traction.
Green Chemistry
Environmental sustainability is becoming a priority in peptide manufacturing.
| Innovation | Environmental Benefit |
|---|---|
| Solvent recycling systems | Reduce DMF and NMP consumption by 80% |
| Enzymatic coupling | Eliminate chemical coupling reagents |
| Water-based synthesis | Reduce organic solvent use |
| Flow chemistry | Less waste per coupling cycle |
| Biocatalytic approaches | Milder conditions, less waste |
Automation and Digitalization
Advanced automation is reducing manual labor and improving consistency:
- Fully automated peptide synthesizers with in-line analytics
- Robotic sample handling and processing
- Digital batch records with electronic signatures
- Real-time process monitoring with PAT (process analytical technology)
- Predictive maintenance using AI and machine learning
Workforce Challenges
Talent Shortage
The biggest risk to capacity expansion timelines is the shortage of skilled peptide manufacturing professionals. You cannot operate a new facility without trained people.
| Role | Estimated Global Shortage | Impact |
|---|---|---|
| Peptide Process Chemists | 2,000+ positions | Delays in process development and tech transfer |
| QC Analysts | 1,500+ positions | Bottleneck in batch release |
| Manufacturing Operators | 3,000+ positions | Cannot run facilities at full capacity |
| Quality Managers | 500+ positions | Compliance risks |
| Process Engineers | 800+ positions | Scale-up delays |
Training Programs
Companies and universities are responding with accelerated training programs for peptide manufacturing. These programs cover SPPS fundamentals, GMP operations, analytical methods, and equipment operation.
Some CDMOs are building their own internal training academies. Others are partnering with community colleges and technical schools to develop certificate programs.
Salary Competition
The talent shortage is driving up salaries across all peptide manufacturing roles. Senior peptide chemists have seen salary increases of 15% to 20% over the past two years.
Maria Gonzalez, VP of Manufacturing Operations at a major CDMO put it plainly: "We can build the buildings and install the equipment. What we cannot manufacture is people with 10 years of peptide manufacturing experience. The workforce is the true bottleneck."
Regional Manufacturing Hubs
North America
The United States is adding significant peptide manufacturing capacity, particularly in North Carolina, New Jersey, and Indiana. Tax incentives and the proximity to pharma headquarters drive investment.
Europe
Switzerland (Bachem headquarters), Denmark (Novo Nordisk), and Sweden (PolyPeptide) remain European hubs. New capacity is also being added in Germany, France, and Ireland.
Asia-Pacific
China and India are emerging as major peptide manufacturing centers. Lower labor costs and growing domestic markets make these regions attractive for both domestic companies and Western CDMOs building satellite facilities.
South Korea's entry through Samsung Biologics signals that established biologics manufacturers see peptide manufacturing as a growth opportunity.
Impact on the Outsourcing Market
Longer Lead Times
CDMO lead times for new peptide projects have stretched to 12 to 18 months at many facilities. Companies need to plan their outsourcing strategy earlier in the development process.
Pricing Trends
Manufacturing costs per gram have actually decreased slightly despite the capacity crunch, as larger-scale production drives efficiencies. However, the premium for guaranteed capacity and priority scheduling has increased.
Long-Term Agreements
More companies are signing multi-year manufacturing agreements with CDMOs to secure capacity. These agreements include minimum volume commitments in exchange for guaranteed production slots.
FAQ
When will the peptide manufacturing shortage end?
The supply-demand gap is expected to narrow significantly by 2027 to 2028 as major facility expansions come online. However, continued market growth means that capacity may remain tight for premium GMP services even after the gap closes.
How long does it take to build a new peptide manufacturing facility?
From initial planning to GMP-ready production, a new facility takes 3 to 4 years. This includes design and permitting (6 to 12 months), construction (18 to 24 months), equipment installation and qualification (6 to 12 months), and process validation (3 to 6 months).
Can existing pharma facilities be converted to peptide manufacturing?
Partial conversion is possible for some facility types. Clean rooms, utilities, and warehouse space may be reusable. However, the specialized equipment (peptide synthesizers, HPLC systems, lyophilizers) must be newly purchased and installed. The conversion process typically takes 12 to 18 months.
How much does it cost to build a peptide manufacturing facility?
A mid-scale GMP peptide manufacturing facility costs $100 million to $300 million to build. A large-scale facility with multiple production lines can exceed $500 million. These costs include building construction, equipment, utility systems, quality infrastructure, and initial staffing.
Will new technologies reduce the need for manufacturing capacity?
Continuous flow synthesis and other innovations will improve efficiency, producing more peptide per unit of capacity. However, market demand is growing faster than efficiency improvements, so new physical capacity is still essential.
Topics
Dr. Michael Torres
Healthcare Staffing Consultant
MD, Healthcare Administration | 11 years in clinical staffing
Former physician turned healthcare staffing specialist. Advises peptide clinics and regenerative medicine practices on credentialing, provider placement, and team structure.
Reviewed by Dr. Michael Torres, MD, April 2026